Dilliard Sean A, Siegwart Daniel J
Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX USA.
Department of Biomedical Engineering, The University of Texas Southwestern Medical Center, Dallas, TX USA.
Nat Rev Mater. 2023;8(4):282-300. doi: 10.1038/s41578-022-00529-7. Epub 2023 Jan 19.
Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of medicines that directly reprogramme the central dogma of biology to prevent and treat disease. However, multiple biological barriers normally impede the intracellular delivery of nucleic acids, necessitating the use of a delivery system. Lipid and polymer nanoparticles represent leading approaches for the clinical translation of genetic drugs. These systems circumnavigate biological barriers and facilitate the intracellular delivery of nucleic acids in the correct cells of the target organ using passive, active and endogenous targeting mechanisms. In this Review, we highlight the constituent materials of these advanced nanoparticles, their nucleic acid cargoes and how they journey through the body. We discuss targeting principles for liver delivery, as it is the organ most successfully targeted by intravenously administered nanoparticles to date, followed by the expansion of these concepts to extrahepatic (non-liver) delivery. Ultimately, this Review connects emerging materials and biological insights playing key roles in targeting specific organs and cells in vivo.
基于核酸生物分子的基因药物是一类迅速兴起的药物,它们直接重新编程生物学中心法则以预防和治疗疾病。然而,多种生物屏障通常会阻碍核酸的细胞内递送,因此需要使用递送系统。脂质和聚合物纳米颗粒是基因药物临床转化的主要方法。这些系统绕过生物屏障,并利用被动、主动和内源性靶向机制促进核酸在靶器官的正确细胞中的细胞内递送。在本综述中,我们重点介绍了这些先进纳米颗粒的组成材料、它们携带的核酸货物以及它们在体内的运输过程。我们讨论了肝脏递送的靶向原则,因为肝脏是迄今为止静脉注射纳米颗粒最成功靶向的器官,随后将这些概念扩展到肝外(非肝脏)递送。最终,本综述将在体内靶向特定器官和细胞方面发挥关键作用的新兴材料和生物学见解联系起来。